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CXCR4Activation of the CXCL12–CXCR4 pathway is crucial for the migration of hematopoietic stem cells,
various immune cells, and malignant tumor cells. Here, we show that another CXC chemokine,
CXCL14, speciﬁcally binds to CXCR4 with high afﬁnity and inhibits the CXCL12-mediated chemotaxis
of human leukemia-derived cell lines and CD34+ hematopoietic progenitor cells. Thus, CXCL14 func-
tions as a natural inhibitor of CXCL12. Our observations suggest that CXCL14 represents, along with
CXCR7, molecules that co-evolved with the CXCL12–CXCR4 axis to modulate important physiological
processes in development, stem cell maintenance, and immune responses.
Structured summary of protein interactions:
CXCR4 physically interacts with CXCL14 anti bait coimmunoprecipitation by (View interaction).
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction iDCs [12,13] and natural killer cells [14], but not T cells. CXCL14Chemokines are critical regulators of cell migration during
organogenesis and immunosurveillance [1,2]. Among 17 CXC-type
chemokines, CXCL12 and CXCL14 are considered primordial che-
mokines based on their strong sequence conservation throughout
evolution and their role in homeostasis [3]. Two speciﬁc receptors
for CXCL12 are known, CXCR4 and CXCR7. The interaction of
CXCL12 with its two receptors regulate the homing of hematopoi-
etic stem cells in bone marrow, the migration of primordial germ
cells and neural progenitors in developing embryos, and the traf-
ﬁcking of a wide variety of cells, including immature dendritic cells
(iDCs), pre-B cells, T cells and endothelial cells [4]. In addition, the
CXCL12–CXCR4 signaling axis is utilized by various types of cancer
cells to promote growth, angiogenesis, and metastasis [5].
In contrast to CXCL12, speciﬁc receptors for CXCL14 have not
yet been identiﬁed. CXCL14 has been implicated in the mainte-
nance of tissue macrophages, cancer progression, and metabolic
regulation [6]. Interestingly, CXCL14 is downregulated in malig-
nant tumors [7,8], and it has been shown to exhibit tumor suppres-
sor activity [9,10]. CXCL14 chemoattracts tissue macrophages [11],binds to monocytes, iDCs and endothelial cells [12,13]. Low afﬁnity
binding sites (Kd = about 300 nM) for CXCL14 on endothelial cells
are competitively blocked by heparin, suggesting that cell surface
glycosaminoglycan heparin moieties are low afﬁnity CXCL14
receptors [12,15]. More importantly, iDCs express high-afﬁnity
CXCL14 binding molecules that are presumptive functional CXCL14
receptors [12]. These high-afﬁnity binding sites were not compet-
itively inhibited by CXCL12, CXCL10 or CXCL8 [12], implicating
that CXCL14 receptor may be different from G-protein coupled
receptors (GPCRs) for these CXC chemokines. However, previous
studies have not clariﬁed whether or not CXCL14 utilizes CXCR4
as a receptor component.
In this study, we demonstrate that CXCL14 speciﬁcally binds to
CXCR4 with high afﬁnity and inhibits the CXCL12-mediated che-
motaxis of human bone marrow derived hematopoietic progeni-
tors and leukemia-derived cells. We propose that CXCL14 is a
natural inhibitor of the CXCL12–CXCR4 axis.
2. Materials and methods
2.1. Small interfering RNA (siRNA)-mediated knockdown of CXCR4 and
cDNA overexpression experiments
To stably express siRNA, human monocytic leukemia-derived
THP-1 cells were infected with pRePS retroviral vector encoding
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The target sequences of the sense oligonucleotide are as follows:
human CXCR4 50-AAGCATGACGGACAAGTACAG-30. Infected cells
were selected in growth medium containing puromycin (2 mg/
ml; Sigma, St. Louis, MO), and a representative clone exhibiting
the best knockdown efﬁciency was used for each gene. For overex-
pression or cDNA rescue experiments of CXCR4, THP-1 or THP-1-
CXCR4-knckdown cells were infected with pMY-CXCR4-ires-EGFP
or pMY-CXCR4 (siRNA resistant)-ires-EGFP retroviral vector, respec-
tively, according to the published method [17]. Detailed method
for the vector construction was described in Supplementary mate-
rials. EGFP bright cell fractions were separated on a FACSAria (BD
Biosciences, San Jose, CA).
2.2. Chemotaxis assay
THP-1, Jurkat, BaF/3, or human CD34+ bone marrow cells were
washed and resuspended at 106 cells/ml in RPMI-1640 containing
0.1% fatty acid-free BSA (Sigma) and 20 mM HEPES (pH 7.5) (Invit-
rogen, Carlsbad, CA) in the presence or absence of 100 nM human
CXCL14 (PeproTech, Rocky Hill, NJ). The wells of a 24-well culture
plate were ﬁlled with 550 ll of the same media containing 10 nM
human CXCL12 (Peprotech), 20 nM human CCL2 (Peprotech), or
10 nM human CXCL8 (Peprotech). Chemotaxicell ﬁlters (5 mm
pore size; Kurabo, Osaka, Japan) were placed in each well and test
cells (200 ll) were added to the upper chamber. The plate was then
incubated for 2 h at 37 C. Cells remaining on the upper surface of
the chamber were scraped off. Cells that had migrated to the bot-
tom surface of the chamber were stained with Diff-Quik (Kokusai
Shiyaku, Kobe, Japan) and counted under a microscope. The num-
bers of cells that penetrated the wells were also counted and added
to the cell number on the bottom surface of the chamber. In some
experiments, total number of migrated cells toward CXCL14 con-
taining medium was divided by the cell number migrated in med-
ium alone and this value was used as chemotactic index.
2.3. Binding assay using 125I-labeled CXCL14
Recombinant human CXCL14 (5 lg) was suspended in 50 ll
0.1 M borate buffer (pH 8.2) containing 0.01% Tween 20 (Nacalai
Tesque, Kyoto, Japan). The mixture was reacted with Bolton-Hun-
ter reagent [125I] (9.25 MBq; Perkin Elmer, Waltham, MA) and incu-
bated on ice for 2 h. The reaction mixture was applied to a D-Salt
polyacrylamide desalting column with a 1.8 K molecular weight
cut-off (Pierce, Rockford, IL) and highly radioactive fractions
(2 ml) were taken as 125I-labeled CXCL14. Binding assays were
carried out according to the previously described method [15]. In
brief, 5  105 cells were suspended in 50 ll RPMI-1640 containing
0.1% fatty acid-free BSA and 20 mM HEPES (pH 7.5) and incubated
on ice for 2 h with 50 ll 125I-labeled CXCL14 in the presence or ab-
sence of 3 lM unlabeled CXCL14. For the cold competition of 125I-
CXCL14, a synthetic CXCL14 analog (49Gly) was used [18]. Cells
were centrifuged at 7500g on a 150 ll oil cushion in a 0.4 ml
polyethylene tube. Radioactivity in the tip fragment was measured
using a WIZARD2 gamma counter (Perkin Elmer). Dissociation con-
stants of the binding assays were calculated using GraphPad Prism
software (GraphPad Software, La Jolla CA).
2.4. Ligand immunopreciptiation and chemical crosslinking
experiments
Direct association of CXCR4 with 125I-labeled CXCL14 was eval-
uated by transient cDNA transfection and immunoprecipitation
experiments in COS-7 cells. Cells were transfected with PCS2+
CXCR4-FLAG and CXCR4v2-FLAG (information in Supplementary
materials), and lysed in lysis buffer [50 mM Tris–HCl (pH 7.5),150 mM NaCl, 10 mM EDTA, 15% (v/v) glycerol, and 1% n-dodecyl
b-d-maltoside (Dojindo, Kumamoto, Japan) containing complete
protease inhibitor cocktail (Roche Applied Science)]. Cell lysates
were incubated with mouse anti-FLAG antibody conjugated M2
agarose (Sigma) after the removal of insoluble materials to purify
CXCR4 proteins. Immunoprecipitates were incubated with 1 nM
125I-labeled CXCL14 for 2 h on ice, washed, and analyzed by SDS–
PAGE followed by autoradiography. Chemical crosslinking experi-
ments of THP-1 cells with 125I-labeled CXCL14 were performed
as described previously [19] using a DSS crosslinker (Pierce).
For the cell surface labeling experiment, COS-7 cells transiently
transfected with pCS2+ expression vector carrying human CXCR4-
FLAG, CXCR7-FLAG, or CCR1-FLAG cDNA were incubated with EZ-
link NHS-biotin (Pierce) for 30 min on ice. Biotinylated proteins
were extracted and used for immunoprecipitation.
2.5. Statistical analyses
All statistical analyses were performed using ANOVA repeated
measures analysis using functions on Microsoft Excel. A P-value
of <0.05 was considered signiﬁcant for the unpaired Student’s t-
test. Each value in ﬁgures represents the mean ± standard errors.
⁄P < 0.05, ⁄⁄P < 0.01, or not signiﬁcant to the reference sample.
3. Results
3.1. CXCL14 binds to CXCR4 with high afﬁnity
During the course of our CXCL14 receptor search, we noticed
that CXCR4 expression and CXCL14 binding sites were coordinately
increased in C2C12 cells by forskolin treatment (K.T., K.S., and T.H.,
manuscript in preparation). Therefore, we prepared 125I-labeled
CXCL14 and performed conventional binding assays. THP-1 cells
were found to possess high afﬁnity binding sites (Kd = 14.7 nM)
for 125I-CXCL14 (Fig. 1A). To explore relationship between CXCR4
and CXCL14, a stable transfectant of CXCR4 cDNA was established
(THP-1CXCR4), and tested the binding capacity of 125I-labeled
CXCL14. As shown in Fig. 1A, signiﬁcantly increased amount of
125I-CXCL14 was bound to THP-1CXCR4 cells when compared to
parental THP-1 cells. Conversely, we established THP-1 cells that
stably express CXCR4 siRNA (Supplementary Fig. 1A and B). Knock-
down of CXCR4 led to a reduction in 125I-CXCL14 binding at con-
centrations in the high-afﬁnity range (Fig. 1A), which was
rescued by the expression of siRNA-resistant CXCR4 (Supplemen-
tary Fig. 1A and C). CXCL12 is known to bind CXCR4 as well as
CXCR7. We found that a transient transfection of CXCR4 cDNA in-
creased the speciﬁc binding of 125I-CXCL14 in COS-7 cells
(Fig. 1B). In contrast, transfection of CXCR7 or CCR1 cDNA did not
signiﬁcantly change the 125I-CXCL14 binding capacity (Fig. 1B).
We conﬁrmed cell surface expression of each GPCR in these exper-
imental settings (Supplementary Fig. 2).
Next, we examined the expression of CXCR4 and 125I-CXCL14
binding of primary hematopoietic cells of mouse origin. FACS anal-
ysis using anti-CXCR4 antibody revealed that CD3dim T cells, Mac1+
myeloid cells, B220+/IgM immature B cells, and B220+/IgM+ ma-
ture B cells expressed a higher amount of CXCR4 on cell surface,
whereas CD3bright T cells displayed a low level of CXCR4 (Fig. 1C).
Consistent with our data, binding of 125I-CXCL14 in CD3bright T cells
was lowest among these ﬁve populations (Fig. 1C).3.2. CXCR4 is a speciﬁc and major binding component of the CXCL14
receptor
To further conﬁrm the direct interaction between CXCR4 and
CXCL14, we performed chemical crosslinking experiments using
Fig. 1. CXCL14 binding capacity of gene-manipulated cell lines and primary hematopoietic cells. (A) 125I-CXCL14 binding properties of CXCR4-transfected as well as CXCR4-
knockdown THP-1 cells (n = 4–6). (B) 125I-CXCL14 binding of CXCR4, CXCR7, or CCR1 cDNA-transfected COS-7 cells (n = 6). (C) 125I-CXCL14 binding of CD3bright and CD3dim T
cells from thymus, B220+/IgM+ mature B cells from spleen, and B220+/IgM immature B cells and Mac1+ myeloid cells from bone marrow. The amount of CXCR4 on cell
surface (red bar: right axis) and binding capacity of 125I-CXCL14 (blue bar: left axis) in each cell population was determined (n = 3). In A–C, the binding reactions were carried
out in the presence or absence of an excess amount of unlabeled CXCL14 and the counts for speciﬁc binding are shown. In A and B, ⁄P < 0.05; ⁄⁄P < 0.01 compared to parental
THP-1 cells (A) or untransfected COS-7 cells (B).
Fig. 2. Direct interaction of 125I-CXCL14 with CXCR4. (A) Chemical crosslinking of CXCR4-transfected THP-1 cells and parental THP-1 cells with 30 nM of 125I-CXCL14 in the
presence or absence of 3 lM unlabeled CXCL14. Red arrowheads indicate CXCR4 species crosslinked with dimeric and monomeric 125I-CXCL714 (64 and 51 kDa), respectively.
Blue arrowheads show the positions of free 125I-CXCL14. (B) In vitro binding of 1 nM 125I-CXCL14 to anti-FLAG immunoprecipitates of indicated COS-7 cell lysates.
Autoradiography after separation on PAGE in the presence of SDS is shown. (C) Binding competition between various chemokines and 1 nM 125I-CXCL14 with CXCR4-FLAG or
CXCR4v2-FLAG immunoprecipitates prepared from transfected COS-7 cells (n = 3–5). Binding reactions were carried out in the presence or absence of an excess amount of
unlabeled CXCL14 and the counts for speciﬁc binding are shown. ⁄⁄P < 0.01 compared to the PBS controls.
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64 kDa) that were increased by the overexpression of CXCR4
(Fig. 2A). Since the molecular weights of the crosslinked proteins
corresponded to those of CXCR4–CXCL14 (51 kDa) and CXCR4–
CXCL14–CXCL14 (60 kDa), it is likely that CXCR4 interacts with
monomeric as well as homodimeric CXCL14.
We next performed in vitro binding assays with afﬁnity-puri-
ﬁed CXCR4. The human CXCR4 gene produces two splice variants,
CXCR4 and CXCR4v2. FLAG-tagged versions of both variants were
produced from plasmid-transfected COS-7 cells, afﬁnity-puriﬁed
with anti-FLAG antibody-conjugated agarose, and incubated with
125I-CXCL14. 125I-CXCL14 was co-immunoprecipitated with
CXCR4-FLAG or CXCR4v2-FLAG protein, and such interaction was
abrogated in the presence of an excess amount of unlabeled
CXCL14 (Fig. 2B). Moreover, complex formation between 125I-
CXCL14 (1 nM) and CXCR4-FLAG or CXCR4v2-FLAGwas speciﬁcally
inhibited by 100 nM of CXCL14, but not by CXCL12, CCL2, or CXCL8
(Fig. 2C). Taken together, we concluded that CXCR4 is a speciﬁc and
major binding component of the CXCL14 receptor.3.3. CXCL14 acts as a natural inhibitor of CXCL12
Since CXCL14 physically interacts with CXCR4, we next investi-
gated whether CXCL14 regulates the chemotactic activity of
CXCL12. In THP-1, Jurkat (human T cell leukemia derived cell line),
and BaF/3 (mouse pre-B cell line) cells, the presence of CXCL14 in
the upper chamber of Chemotaxicell almost completely blocked
the CXCL12-mediated cell migration in a dose-dependent fashion
(Fig. 3A and B). In the case of THP-1 cells, CXCL14 inhibited the
CXCL12-mediated chemotaxis with an IC50 of 7.2 nM, which is sim-
ilar to the Kd of 125I-CXCL14. Addition of CXCL14 to both upper and
lower chambers of Chemotaxicell yielded similar inhibition (data
not shown). CXCL14 did not affect the chemotactic response of
THP-1 cells to CCL2 or CXCL8 (Fig. 3A). It is well known that the
CXCL12/CXCR4 signaling pathway is crucial for the regulation of
hematopoietic stem cell trafﬁcking. Similar to the cases of hemato-
poietic cell lines, CXCL14 also repressed the CXCL12-driven migra-
tion of human bone marrow-derived CD34+ hematopoietic
progenitor cells (Fig. 3C).
Fig. 3. Cross-competition of the CXCL12-mediated chemotaxis by CXCL14. (A)
Migratory response of THP-1 cells to 10 nM CXCL12, 20 nM CCL2 or 10 nM CXCL8 in
the presence or absence of 100 nM CXCL14 (n = 3–5). (B) Chemotactic responses of
various hematopoietic cell lines to 10 nM CXCL12 in the presence of various
concentrations of CXCL14 in the upper chamber of Chemotaxicell (n = 4). (C)
Chemotactic response of human CD34+ hematopoietic progenitor cells to 10 nM
CXCL12 in the presence or absence of 100 nM CXCL14 in the upper chamber (n = 4).
In A and C, total number of migrated cells toward chemokine containing medium
was divided by the cell number migrated in medium alone (Chemotactic index). In
A–C, ⁄P < 0.05; ⁄⁄P < 0.01; n.s., not signiﬁcant compared to the sample indicated (A,
C) or the value in the absence of chemokine (B).
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Despite the potential clinical signiﬁcance of CXCL14, especially
for the tumor suppression and attenuation of the obesity-induced
diabetes, its receptors have not yet been identiﬁed. This also pre-
vents us to understand molecular mechanisms behind the physio-
logical functions of CXCL14. Here, we show that CXCL14
speciﬁcally binds to CXCR4 with high afﬁnity and inhibits the
CXCL12-mediated cell migration. Of all 48 human chemokines,
only CXCL12 and CXCL14 are strongly conserved all the way backto the zebraﬁsh [3], while CXCR4 and CXCR7 are also conserved
in the zebraﬁsh. This suggests that CXCL14 and CXCR7 represent
proteins whose function includes the ‘ﬁne tuning’ of the CXCL12/
CXCR4 axis. The sequence conservation across species of CXCL12,
CXCL14, CXCR4 and CXCR7 strongly suggests that they have
evolved together and form a system where the CXCL14 and CXCR7
may regulate the function of the CXCL12–CXCR4 signaling axis.
There is precedent for other natural antagonists within the che-
mokine superfamily: e.g., CXCL9, 10 and 11 are natural antagonists
for CCR3 [20], and CCL11 is a natural antagonist for CXCR3 [21]. It
has been shown that the dimeric form of CXCL12 exhibits a shift to
an inverse agonist for CXCR4 and inhibits the chemotactic response
by monomeric CXCL12 [22]. As we detected a complex of dimeric
CXCL14 with CXCR4, the inhibitory action of CXCL14 might be re-
lated to its dimeric form. Detailed structure–function study for the
interaction between CXCL14 and CXCR4 will be a critical step to
better understand this unique chemokine and to develop novel
therapeutic modulators of the CXCL12–CXCR4 axis.
Recently, administration of the dimeric CXCL12 was shown to
inhibit the metastasis of colorectal carcinoma cells in a mouse
xenotransplantation model [22]. Since the activity of CXCL14 is
analogous to the CXCL12 dimer, CXCL14 could suppress the tumor
growth via speciﬁc inhibition of the CXCL12–CXCR4 signaling. In
support of this hypothesis, CXCL14 possesses the tumor suppres-
sive activity against certain types of carcinoma cells [9,10].
It remains unclear where CXCL14modulates the CXCL12–CXCR4
signaling in physiological situations. One candidate is its involve-
ment in the neural development. Both Cxcl14 and Cxcl12 mRNAs
are co-expressed during early embryogenesis and in the fetal brain
in carp [3] and chickens [23]. Banisadr et al. recently reported that
CXCL14 is expressed in GABAergic interneurons in the dentate
gyrus of adult mice and inhibits GABAergic transmission to neural
stem/progenitor cells [24]. In sharp contrast, CXCL12 was shown
to enhance the activity of synaptically released GABA. Given that
CXCL14 is a natural inhibitor of CXCL12, when and where these
two chemokines are produced may be important for the normal
development and region-speciﬁc regulation of the neural function.
We demonstrated that CXCR4 is the ligand binding receptor for
CXCL14. However, CXCR4 alone is not sufﬁcient for driving the
CXCL14-mediated chemotaxis, since Jurkat cells and normal T cells
express CXCR4 but do not respond to CXCL14 in conventional che-
motaxis assays. It was also true when we employed the highly sen-
sitive cell migration assay with using the anti-CXCL14 monoclonal
antibody MAB730 [15] (data not shown). Presumably, an addi-
tional receptor or signal transducer molecule could be required
for the CXCL14 signal transduction in combination with CXCR4. It
is of notice that we have previously revealed that CXCL14 null fe-
male mice exhibit lighter body weight, resistance to obesity-in-
duced diabetes, and abnormal feeding behavior in novel
environments [25,26]. Such metabolism-related abnormality has
not been reported in CXCL12 or CXCR4-deﬁcient mice. Again,
CXCL14-speciﬁc biological activities would be exerted via a puta-
tive CXCL14-speciﬁc receptor complex. Characterization of a candi-
date GPCR is underway in this laboratory.Conﬂict of interest
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